$SEEL
Seelos Therapeutics Inc Stock $seel

$seel Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000101749115000069 Filed on August 05, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$1.273M	$462.0K	$5.454M
YoY Change	-32.93%	-91.53%	357.55%
Cost Of Revenue	$142.0K	$509.0K	$75.00K
YoY Change		578.67%	-89.32%
Gross Profit	$1.131M	-$47.00K	$5.379M
YoY Change	-19.96%	-100.87%	997.76%
Gross Profit Margin	88.85%	-10.17%	98.62%
Selling, General & Admin	$2.410M	$2.670M	$2.880M
YoY Change	-11.4%	-7.29%	-23.2%
% of Gross Profit	213.09%		53.54%
Research & Development	$4.611M	$3.107M	$2.103M
YoY Change	145.79%	47.74%	37.0%
% of Gross Profit	407.69%		39.1%
Depreciation & Amortization	$70.00K	$80.00K	$20.00K
YoY Change	16.67%	300.0%	0.0%
% of Gross Profit	6.19%		0.37%
Operating Expenses	$7.023M	$5.776M	$4.134M
YoY Change	52.84%	39.72%	-9.0%
Operating Profit	-$5.892M	-$5.823M	$1.245M
YoY Change	85.17%	-567.71%	-130.72%
Interest Expense	-$267.0K	-$170.0K	-$69.00K
YoY Change	506.82%	146.38%	-67.61%
% of Operating Profit			-5.54%
Other Income/Expense, Net	$858.0K	$578.0K	-$40.00K
YoY Change	1616.0%	-1545.0%	21.21%
Pretax Income	-$5.030M	-$5.250M	$1.210M
YoY Change	60.7%	-533.88%	-129.58%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$5.034M	-$5.245M	$1.877M
YoY Change	61.71%	-379.44%	-147.7%
Net Earnings / Revenue	-395.44%	-1135.28%	34.42%
Basic Earnings Per Share		-$0.10	$0.05
Diluted Earnings Per Share	-$29.59M	-$0.10	$0.05
COMMON SHARES
Basic Shares Outstanding	50.41M shares	50.41M shares	37.90M shares
Diluted Shares Outstanding		50.41M shares	37.91M shares

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.810M	$7.430M	$17.42M
YoY Change	-63.94%	-57.35%	-29.64%
Cash & Equivalents	$5.809M	$7.433M	$17.42M
Short-Term Investments
Other Short-Term Assets	$1.640M	$1.310M	$990.0K
YoY Change	47.75%	32.32%	65.0%
Inventory	$142.0K	$411.0K	$377.0K
Prepaid Expenses
Receivables	$575.0K	$664.0K	$49.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.165M	$9.816M	$18.83M
YoY Change	-55.55%	-47.88%	-28.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.294M	$1.425M	$1.347M
YoY Change	-1.9%	5.79%	137.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$141.0K	$149.0K	$105.0K
YoY Change	33.02%	41.9%	176.32%
Total Long-Term Assets	$1.435M	$1.574M	$1.452M
YoY Change	0.7%	8.4%	140.4%
TOTAL ASSETS
Total Short-Term Assets	$8.165M	$9.816M	$18.83M
Total Long-Term Assets	$1.435M	$1.574M	$1.452M
Total Assets	$9.600M	$11.39M	$20.29M
YoY Change	-51.51%	-43.85%	-24.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$420.0K	$450.0K	$1.130M
YoY Change	-65.57%	-60.18%	-22.6%
Accrued Expenses	$2.869M	$2.532M	$1.807M
YoY Change	57.21%	40.12%	-33.0%
Deferred Revenue
YoY Change
Short-Term Debt	$2.680M	$920.0K	$1.180M
YoY Change	123.33%	-22.03%	-54.09%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.855M	$4.974M	$6.969M
YoY Change	7.34%	-28.63%	-36.66%
LONG-TERM LIABILITIES
Long-Term Debt	$7.190M	$3.960M	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$190.0K	$246.0K	$69.00K
YoY Change	227.59%	256.52%	-48.89%
Total Long-Term Liabilities	$190.0K	$246.0K	$69.00K
YoY Change	227.59%	256.52%	-48.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.855M	$4.974M	$6.969M
Total Long-Term Liabilities	$190.0K	$246.0K	$69.00K
Total Liabilities	$17.51M	$14.64M	$7.038M
YoY Change	124.5%	108.01%	-47.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$306.5M	-$301.5M	-$269.5M
YoY Change	12.47%	11.9%	2.17%
Common Stock	$298.6M	$298.3M	$281.3M
YoY Change	4.95%	6.03%	1.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.911M	-$3.250M	$11.85M
YoY Change
Total Liabilities & Shareholders Equity	$9.600M	$11.39M	$20.29M
YoY Change	-51.51%	-43.85%	-24.65%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$5.034M	-$5.245M	$1.877M
YoY Change	61.71%	-379.44%	-147.7%
Depreciation, Depletion And Amortization	$70.00K	$80.00K	$20.00K
YoY Change	16.67%	300.0%	0.0%
Cash From Operating Activities	-$6.590M	-$8.610M	-$4.630M
YoY Change	61.52%	85.96%	-9.22%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	-$20.00K	-$70.00K
YoY Change	-57.14%	-71.43%	-12.5%
Acquisitions
YoY Change
Other Investing Activities	$10.00K	$0.00	$680.0K
YoY Change		-100.0%	518.18%
Cash From Investing Activities	-$20.00K	-$20.00K	$600.0K
YoY Change	-66.67%	-103.33%	1400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.990M	-90.00K	-1.040M
YoY Change	75.7%	-91.35%	-106.57%
NET CHANGE
Cash From Operating Activities	-6.590M	-8.610M	-4.630M
Cash From Investing Activities	-20.00K	-20.00K	600.0K
Cash From Financing Activities	4.990M	-90.00K	-1.040M
Net Change In Cash	-1.620M	-8.720M	-5.070M
YoY Change	24.62%	71.99%	-147.03%
FREE CASH FLOW
Cash From Operating Activities	-$6.590M	-$8.610M	-$4.630M
Capital Expenditures	-$30.00K	-$20.00K	-$70.00K
Free Cash Flow	-$6.560M	-$8.590M	-$4.560M
YoY Change	63.59%	88.38%	-9.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	apri	Accrued License Fees AccruedLicenseFees	2500000	USD
CY2015Q2	apri	Accrued License Fees AccruedLicenseFees	0	USD
	apri	Increase Decrease In Short Term Liability Arising From Deconsolidation Of Subsidiaries IncreaseDecreaseInShortTermLiabilityArisingFromDeconsolidationOfSubsidiaries	-2000000	USD
	apri	Increase Decrease In Short Term Liability Arising From Deconsolidation Of Subsidiaries IncreaseDecreaseInShortTermLiabilityArisingFromDeconsolidationOfSubsidiaries	0	USD
	apri	Increase Decreasein Deferred Rental Incomeand Other Noncurrent Assets IncreaseDecreaseinDeferredRentalIncomeandOtherNoncurrentAssets	14000	USD
	apri	Increase Decreasein Deferred Rental Incomeand Other Noncurrent Assets IncreaseDecreaseinDeferredRentalIncomeandOtherNoncurrentAssets	9000	USD
CY2014Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	838000	USD
CY2015Q2	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	1257000	USD
	apri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm	P2Y2M7D
	apri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermOne	P3Y6M7D
	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.0360
	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.1154
CY2015Q2	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	6859682	shares
CY2015Q2	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	3.83
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	0.00
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	1.82
CY2014Q4	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.83
CY2015Q2	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.21
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice	0.00
CY2014	apri	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms1 SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1	P2Y8M6D
CY2014Q1	apri	Stock Returned From Contract Settlement Shares StockReturnedFromContractSettlementShares	388888	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	298209000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	545000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1036000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	325000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	613000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001017491
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50414481	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	APRICUS BIOSCIENCES, INC.
	dei	Trading Symbol TradingSymbol	APRI
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	860000	USD
CY2015Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	446000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	678000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	664000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	106000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	94000	USD
CY2014Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1112000	USD
CY2015Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	920000	USD
CY2014Q4	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	126000	USD
CY2015Q2	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	108000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4555000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2532000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	625000	USD
CY2015Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	506000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	291727000	USD
CY2014Q4	us-gaap	Assets Assets	14809000	USD
CY2015Q2	us-gaap	Assets Assets	11390000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	13289000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	9816000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	28000	USD
CY2014Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	5000	USD
CY2015Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	2000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21405000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17420000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11400000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7433000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3985000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3967000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	675000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-3000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	0	USD
	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	50000	USD
CY2015Q2	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	0	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5936000	USD
CY2015Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	9881659	shares
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44330006	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50414481	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44330006	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50414481	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	44000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	50000	USD
CY2014Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	75000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	75000	USD
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	509000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	742000	USD
CY2014Q2	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	846000	USD
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	846000	USD
CY2015Q2	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2014Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	312000	USD
CY2015Q2	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	223000	USD
CY2014Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	176000	USD
CY2015Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	180000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	41000	USD
CY2015Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	21000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	226000	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	157000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1000000	USD
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1000000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	40000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	149000	USD
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2015Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4466000	USD
CY2015Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5100000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-611000	USD
CY2014Q2	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	910000	USD
CY2015Q2	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
CY2014Q2	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	0	USD
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.06
	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	50000	USD
	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	0	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2877000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.10
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.24
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	672000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	672000	USD
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.02
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2669000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5765000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	5379000	USD
	us-gaap	Gross Profit GrossProfit	5379000	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	-47000	USD
	us-gaap	Gross Profit GrossProfit	195000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1205000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2057000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5245000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-11657000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.03
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.06
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.10
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.24
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.03
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.02
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	202000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-442000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-10000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-14000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-298000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2024000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-194000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-192000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1200000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-69000	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-422000	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	41000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	136000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-106000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-188000	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	4626000	USD
CY2015Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	3954000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	672000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	542000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	10959000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-382000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-109000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	473000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	384000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	50000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-10000	USD
CY2015Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	100000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	300000	USD
CY2014Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-69000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-176000	USD
CY2015Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-157000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-303000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	USD
CY2015Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	248000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	275000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	411000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	106000	USD
CY2015Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	108000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	169000	USD
CY2015Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	55000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	12890000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	14640000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14809000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11390000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6906000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4974000	USD
CY2014Q2	us-gaap	Licenses Revenue LicensesRevenue	5454000	USD
	us-gaap	Licenses Revenue LicensesRevenue	5454000	USD
CY2015Q2	us-gaap	Licenses Revenue LicensesRevenue	0	USD
	us-gaap	Licenses Revenue LicensesRevenue	350000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4817000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14738000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	1877000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1385000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-5245000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11657000	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-40000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	241000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	578000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	288000	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	153000	USD
CY2015Q2	us-gaap	Notes Payable Current NotesPayableCurrent	919000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	4134000	USD
	us-gaap	Operating Expenses OperatingExpenses	7677000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	5776000	USD
	us-gaap	Operating Expenses OperatingExpenses	12140000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	1245000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2298000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5823000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11945000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	290000	USD
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	481000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	162000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	149000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	358000	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	246000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-24000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	29000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	417000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	735000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	591000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	42000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	432000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	188000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	646000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1028000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2176000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10869000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10900000	USD
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-1525000	USD
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	0	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1430
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	40520	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0169
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0158
	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	50000	USD
	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	83000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1358000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1425000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	17000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	3000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2103000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3547000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3107000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6375000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	290000	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	280000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-289852000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-301509000	USD
CY2014Q2	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2015Q2	us-gaap	Royalty Revenue RoyaltyRevenue	75000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	163000	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	387000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	424000	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	5454000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	5454000	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	462000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	937000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1036000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	614000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8075
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0196
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0139
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	3021977	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6859682	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	9881659	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	756120	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1315828	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.59
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.06
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3956000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4475000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.58
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2050
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4060
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	1919000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	-3250000	USD
CY2014Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	6000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2015Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37907000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37886000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50414000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49031000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37901000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37886000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50414000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49031000	shares

Files In Submission

Name	View Source	Status
0001017491-15-000069-index-headers.html	Edgar Link	pending
0001017491-15-000069-index.html	Edgar Link	pending
0001017491-15-000069.txt	Edgar Link	pending
0001017491-15-000069-xbrl.zip	Edgar Link	pending
apri-20150630.xml	Edgar Link	completed
apri-20150630.xsd	Edgar Link	pending
apri-20150630_cal.xml	Edgar Link	unprocessable
apri-20150630_def.xml	Edgar Link	unprocessable
apri-20150630_lab.xml	Edgar Link	unprocessable
apri-20150630_pre.xml	Edgar Link	unprocessable
apri6301510q.htm	Edgar Link	pending
apri63015ex311.htm	Edgar Link	pending
apri63015ex312.htm	Edgar Link	pending
apri63015ex321.htm	Edgar Link	pending
apri63015ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SEEL
Seelos Therapeutics Inc Stock $seel

2015 Q3 Form 10-Q Financial Statement

#000101749115000069 Filed on August 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL Seelos Therapeutics Inc Stock $seel

2015 Q3 Form 10-Q Financial Statement

#000101749115000069 Filed on August 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL
Seelos Therapeutics Inc Stock $seel